Under the terms of the collaboration agreement, which is non-exclusive to both parties, NEC will provide funding for a Phase I clinical trial.
NEC and Vaximm will co-develop personalized cancer vaccines using NEC's cutting-edge artificial intelligence technology, which is utilized in its Neoantigen Prediction System, and Vaximm's proprietary T-cell immunotherapy technology.
The vaccines are planned to be evaluated in a Phase I clinical trial in various solid tumors.
Vaximm will be responsible for conducting the clinical trial, which is expected to be initiated in 2020.
NEC has the option for development and commercialisation rights to the program worldwide, except for China and other Asian territories outside of Japan.
NEC's neoantigen prediction utilises its proprietary AI which is combined with NEC OncoImmunity AS's bioinformatics pipelines making it the leading neoantigen prediction system in the field.
NEC evaluates candidate neoantigens, which allows it to effectively prioritise numerous candidate neoantigens identified in a single patient.
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development